CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

To further determine genetic mechanisms of KRAS inhibitor (KRASi) resistance, scientists performed KRASi-anchored CRISPR-Cas9 loss-of-function screens in KRASG12D, KRASG12C, KRASG12R, and KRASQ61H mutant PDAC cell lines, using six KRASi, to identify genes that modulate sensitivity to KRAS inhibition.